UCB announces results of Phase IIb lupus study of epratuzumab

Global biopharmaceutical company UCB has announced positive results from its Phase IIb open-label extension study of epratuzumab, which is being developed to treat systemic lupus erythematosus (SLE) or lupus.

Source: Drug Development Technology - June 13, 2013 Category: Pharmaceuticals Source Type: news